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Background
Antigenic variation is a primary obstacle to HIV-1 vaccine
development since antibodies (Ab) directed against the
viral envelope have widely variable and poorly predictable
cross-strain reactivity. The breadth of cross-strain reactivity
is usually estimated by in vitro neutralization of a broad
panel of HIV-1 viral strains by a query antibody. However,
this approach is cumbersome and cannot be scaled up to
assess the more than 60,000 circulating HIV-1 viruses.
Methods
To address this issue, we used in silico docking of a flex-
ible peptide, representing the epitope-containing part of a
viral gp120, to a static crystallographic conformation of an
antigen-combining site of an Ab. This procedure was
applied to predict whether neutralization would occur
between the pair. To train the prototype method we used
a panel of 59 V3 sequence diverse pseudoviruses (psVs)
controlled for masking effects. All psVs had an associated
experimentally derived IC50 value for neutralization by
anti-V3 monoclonal Abs 2219 and 447-52D.
Results
We optimized the method for each of the two Abs by
determining an optimal docking model (optimal bound-
aries of a docking peptide and an optimal Ab crystallo-
graphic conformation) giving the largest area under the
prediction ROC curve (AUC) on the training set of 59
psVs. The prediction accuracy for the optimized method
was then estimated: the AUC was equal to 0.96 (95% CI
(0.91; 1)) for 2219, and to 0.88 (95% CI (0.79; 0.97)) for
447-52D.
Conclusion
The method accurately predicts the neutralization of any
HIV-1 strain by mAbs 2219 or 447-52D based solely on
neutralization assay independent energetics and 3D struc-
tural parameters. The neutralization range of these anti-
V3 mAbs can therefore be precisely determined in silico.
Furthermore, given the fact that mAbs 2219 and 447-52D
have completely different binding modes, we anticipate
that our approach is extensible to other antibody-viral
complexes with known structure.
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